Cricut, Inc. (CRCT) Financial Statements
Cricut, Inc. (CRCT) reported trailing twelve-month revenue of $689.8M (down 3.1% year on year) and net income of $87.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $147.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRCTCricut, Inc.Follow CRCT — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- 14.9
- Dividend yield
- 3.2%
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 1.31 | 0.89 | 0.77 | 0.71 | 0.71 | 0.69 | |
| Gross profit | 0.46 | 0.35 | 0.34 | 0.35 | 0.39 | 0.40 | |
| Research & development | 0.08 | 0.08 | 0.07 | 0.06 | 0.07 | 0.07 | |
| Operating income | 0.19 | 0.08 | 0.07 | 0.08 | 0.10 | 0.11 | |
| Pre-tax income | 0.19 | 0.08 | 0.08 | 0.09 | 0.11 | 0.12 | |
| Income tax | 0.05 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Net income | 0.14 | 0.06 | 0.05 | 0.06 | 0.08 | 0.09 | |
| Diluted EPS ($) | 0.64 | 0.28 | 0.24 | 0.29 | 0.35 | 0.42 | |
| Diluted shares (bn) | 0.220 | 0.221 | 0.220 | 0.216 | 0.217 | — |
USD billions · SEC XBRL
Cricut, Inc. — questions
- What is Cricut, Inc.'s revenue?
- $689.8M over the twelve months to 2026-06-30, down 3.1% year on year, from its 10-Q and 10-K filings.
- What is Cricut, Inc.'s net income?
- $87.7M over the twelve months to 2026-06-30.
- What is Cricut, Inc.'s free cash flow?
- $147.7M over the twelve months to 2026-06-30.
- What are Cricut, Inc.'s diluted earnings per share?
- $0.42 over the twelve months to 2026-06-30.
Every figure on this page comes from Cricut, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.